

- Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res* 1988;48:3282–3287.
- Day GL, Blot WJ, Austin DF, et al. Racial differences in risk of oral and pharyngeal cancer: alcohol, tobacco, and other determinants. *J Natl Cancer Inst* 1993;85:465–473.
- Eliassen AM, Hauff SJ, Tang AL, et al. Head and neck squamous cell carcinoma in pregnant women. *Head Neck* 2013;35:335–342.
- Radoi L, Paget-Bailly S, Guida F, et al. Family history of cancer, personal history of medical conditions and risk of oral cavity cancer in France: the ICARE study. *BMC Cancer* 2013;13:560.
- Sun S, Pollock PM, Liu L, et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. *Int J Cancer* 1997;73:531–536.
- Deganello A, Gitti G, Mannelli G, et al. Risk factors for multiple malignancies in the head and neck. *Otolaryngol Head Neck Surg* 2013;149:105–111.
- Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* 1993;366:704–707.
- Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. *J Clin Oncol* 1998;16:1197–1206.
- Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. *Am J Hum Genet* 1995;56:608–615.
- Wreesmann VB, Estilo C, Eisele DW, et al. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. *ORL J Otorhinolaryngol Relat Spec* 2007;69:218–225.
- van Zeeburg HJ, Snijders PJ, Wu T, et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. *J Natl Cancer Inst* 2008;100:1649–1653.
- Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. *Cancer* 2005;103:1843–1849.
- Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J Clin Oncol* 2008;26:612–619.
- Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2005;14:467–475.
- Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine* 2012;30 Suppl 5:F34–F54.
- Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011;29:4294–4301.
- Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. *Semin Oncol* 2004;31:744–754.
- Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000;92:709–720.
- Hafkamp HC, Manni JJ, Speel EJ. Role of human papillomavirus in the development of head and neck squamous cell carcinomas. *Acta Otolaryngol* 2004;124:520–526.
- Klussmann JP, Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. *Cancer* 2001;92:2875–2884.
- Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. *Clin Cancer Res* 2010;16:1226–1235.
- Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. *J Clin Oncol* 2008;26:3138–3146.
- Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003–2006. *J Infect Dis* 2011;204:566–573.
- D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* 2007;356:1944–1956.
- Walline HM, Komarck C, McHugh JB, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. *JAMA Otolaryngol Head Neck Surg* 2013;139:1320–1327.
- Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. *Head Neck* 2010;32:562–567.
- D'Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. *Int J Cancer* 2007;121:143–150.
- Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA* 2012;307:693–703.
- Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. *J Clin Oncol* 2006;24:2606–2611.
- Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst* 2008;100:261–269.
- Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. *J Natl Cancer Inst* 2008;100:407–420.
- Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. *J Clin Oncol* 2008;26:3138–3146.
- Benson E, Li R, Eisele D, et al. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. *Oral Oncol* 2013 Oct 14.
- Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010;363:24–35.
- Adelstein DJ, Ridge JA, Brizel DM, et al. Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6–7, 2011, Arlington, Virginia. *Head Neck* 2012;34:1681–1703.
- Kimple RJ, Harari PM. Is radiation dose reduction the right answer for HPV-positive head and neck cancer? *Oral Oncol* 2013 Oct 14.
- Duray A, Descamps G, Decaestecker C, et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. *Laryngoscope* 2012;122:1558–1565.
- Stenmark MH, McHugh JB, Schipper M, et al. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. *Int J Radiation Oncol Biol Phys* 2014;88:580–588.
- Dobrosotskaya IY, Bellile E, Spector ME, et al. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. *Head Neck* 2014;36:617–623.
- Spector ME, Gallagher KK, Bellile E, et al. Patterns of nodal metastasis and prognosis in human papillomavirus positive oropharyngeal squamous cell carcinoma. *Head Neck* 2013 Aug 3.
- Spector ME, Gallagher KK, Light E, et al. Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. *Head Neck* 2012;34:1727–1733.
- Hayes N, consortium T. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2013.
- Ragin CC, Reshmi SC, Collin SM. Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line. *Int J Cancer* 2004;110:701–709.
- Cricca M, Venturoli S, Leo E, et al. Molecular analysis of HPV 16 E6/E6I1 spliced mRNAs and correlation with the viral physical state and the grade of the cervical lesion. *J Med Virol* 2009;81:1276–1282.
- Akagi K, Li J, Broutian TR, et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. *Genome Res* 2014;24:185–199.
- Almadori G, Cadoni G, Galli J, et al. Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. *Int J Cancer* 1999;84:188–191.
- Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. *J Natl Cancer Inst* 1998;90:824–832.
- Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol* 2010;11:21–28.
- Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res* 1995;55:4525–4530.
- Merlo A, Herman JG, Mao L, et al. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med* 1995;1:686–692.
- van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21–22 early in head and neck cancer progression. *Cancer Res* 1994;54:1156–1158.
- Taylor D, Koch WM, Zahurak M, et al. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. *Hum Pathol* 1999;30:1221–1225.
- Bradford CR, Kumar B, Bellile E, et al. Biomarkers in advanced larynx cancer. *Laryngoscope* 2014;124:179–187.
- Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. *Otolaryngol Head Neck Surg* 1995;113:408–412.
- Kumar B, Cordell KG, D'Silva N, et al. Expression of p53 and Bel-xL as predictive markers for larynx preservation in advanced laryngeal cancer. *Arch Otolaryngol Head Neck Surg* 2008;134:363–369.
- Carey TE, Van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. *Cancer Res* 1989;49:6098–6107.
- Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. *Nature* 1999;400:464–468.

58. Hahn WC, Weinberg RA. Rules for making human tumor cells. *N Engl J Med* 2002;347:1593–1603.
59. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–525.
60. Liu J, Pan S, Hsieh MH, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. *Proc Natl Acad Sci U S A* 2013;110:20224–20229.
61. Chen C, Wei Y, Hummel M, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. *PLoS One* 2011;6:e16466.
62. Jacobs JJ, Kieboom K, Marino S, et al. The oncogene and Polycomb-group gene *bmi-1* regulates cell proliferation and senescence through the *ink4a* locus. *Nature* 1999;397:164–168.
63. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of *Bmi-1*. *Oral Oncol* 2010;46:158–165.
64. Yu CC, Lo WL, Chen YW, et al. *Bmi-1* regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. *J Oncol* 2011;2011.
65. Clay MR, Tabor M, Owen JH, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. *Head Neck* 2010;32:1195–1201.